Abstracts | 5 methylphenidate group when a refill gap more than 30 days was used. In logistic regression analysis of adherence, we could not find any differences among 4 medication types.
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Abstract Sleep problems are common among patients with attentiondeficit hyperactivity disorder (ADHD), and they are purported to be major causes of behavioral and cognitive dysfunction in ADHD patients. The present study aimed to speculate the relationship between sleep parameters and cognitive function in drug-naïve children with ADHD.
28 patients were recruited to participate in the study, and a polysomnography was used to measure sleep parameters in the subjects. Cognitive measures were collected through utilizing Conners global index for parents version (CGI-P), Wechsler Intelligence Scale for Children-III (WISC-III), and Matching Familiar Figure Test for Korean Children (MFFT-KC). Descriptive statistics were performed to delineate demographic data, sleep parameters and neurocognitive characteristics of ADHD patients.
Spearman's correlation analyses were implemented to speculate the association between sleep parameters and neurocognitive measures. Moreover, multiple regression analyses were used to calibrate the best predictors of cognitive function among sleep parameters. Some meaningful correlations were found with regression models suggesting a possibility of slow wave sleep, stage 2 sleep, REM sleep, limb movement index with arousals as predictors of cognitive function in ADHD patients.
Close association with sleep parameters and cognitive function of ADHD patients can be inferred from our study, and further research should be directed towards clarifying this indispensible link. Abstract Objective: Liver injury is a rare but severe adverse effect of atomoxetine. Most cases of atomoxetine related liver injury were reported in Caucasians. We report a Chinse Han child suffered from acute hepatitis after taking atomoxetine for two months in combination with phenobarbital to enhance our caution of this rare but severe injury related to atomoxetine in clinical practice.
Results:
The 10-year-old girl is a victim of epilepsy, autism, attention deficit/hyperactivity disorder (ADHD) and mild mental retardation. Her epilepsy was diagnosed at the age of 9 months and has been treated by anti-convulsants since then. Current medication for her epilepsy is phenobartial. After entering elementary school, she started to receive medication for ADHD. Because of intolerable side effect of irritability under methylphenidate, atomoxetine 25mg/day was given. Baseline liver function test on revealed total bilirubin 0.2 mg/dl, AST (aspartate aminotransferase) 36 IU/L and ALT (alanine aminotransferase) 19 IU/L. The ADHD symptoms improved significantly. After 3 months treatment of atomoxetine, her follow-up blood test revealed total bilirubin 0.3 mg/dl and ALT 1232 IU/L, and the family was informed immediately. The patient was admitted to pediatric ward of a medical center via emergent department for supportive care on the same day, when atomoxetine was discontinued immediately. Series of studies was done for her hepatitis, including viral hepatitis, immune profile and toxins, which all showed negative findings. Her liver functions improved gradually and atomoxetine-related hepatitis was impressed. The
